Krystal Biotech

KRYS

Last Price
06/16/26, 09:30 AM
 EDT
$
323.79
(
-0.3
%)
(
+
-0.3
%)
Margin of Safety
+
-54.2
%
Modeled Fair Value
$
148.28
Allocation Group
Current Compounder
Modeled Fair Value
$4.499 billion
Allocation Tier
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
An icon graphic of Gouldy the Finch.
#protectYourAssets

Solt DB will launch asset deep dives for all companies in the coverage ecosystem by the end of 2026. These will seamlessly integrate into company-specific financial models, allowing members to determine a company's fair value when specific assets are included or excluded.

Want me to prioritize a specific company or asset? Let me know on Discord or through the contact page.

Last Refined

June 18, 2025
The current model INCLUDES the following assets and assumptions:
The current model is based on operating metrics, including:
  • Component A: Full-year 2025 revenue of $385.683 million and net income of $155.538 million.
The current model EXCLUDES the following assets:
  • KB105 in lamellar ichthyosis (phase 1/2)
  • KB407 in cystic fibrosis (phase 1/2)
  • KB408 in alpha-1 antitrypsin (A1AT) deficiency (phase 1/2)
  • KB707 in solid tumors of the lung (phase 1/2)
  • KB803 in ocular complications of dystrophic epidermolysis bullosa (DEB) (phase 3, label expansion for Vjuvek)
  • KB801 in neurotrophic keratitis (phase 1/2)

SEC Filings